RPG Life Sciences eyes GLP-1 entry, US market via plant acquisitions

The company sharpens its domestic specialty formulations focus and looks to scale APIs through acquisitions, while planning partnership-led GLP-1 launches

RPG Life Sciences is planning to enter India’s fast-emerging GLP-1 diabetes and obesity drug space, while keeping the US market on a medium-term acquisition-led radar, as it eyes ₹2500 crore turnover by 2030.

 

With a new managing director (MD) at the helm, the RPG Group arm is also doubling down on domestic branded formulations, sharpening its specialty focus, apart from building capacities in the active pharmaceutical ingredients (API) space through acquisitions.

 

“We have created a strategic vision built around five pillars, with building big, scalable brands at the core,” said Ashok Nair, MD, RPG Life Sciences.

 

Nair, a pharma industry